Start adding items to your reading lists:or
Save this item to:
This item has been saved to your reading list.
PwC’s Health Research Institute projects that medical cost trend could range from 4% to 10%
Because of the drop in employer healthcare spending in the first half of 2020 and the uncertainty around spending in the second half of the year, HRI is projecting 2021 medical cost trend relative to 2020 estimated healthcare costs, normalizing for COVID-19, rather than actual 2020 costs. HRI has developed three scenarios to guide employers and health plans as they determine 2021 medical cost trend:
Watch PwC's webcast: Medical cost trend in the midst of the COVID-19 pandemic.
Employers are incurring unplanned COVID-19 testing and treatment costs in 2020, and those costs likely will continue in 2021. In 2020, these unplanned costs are expected to be more than offset by the savings from delayed care during the pandemic. An increase in spending is expected in 2021 as the demand for care returns.
Employers have made mental health a priority over the past few years by expanding mental health benefits and working to dispel the stigma around mental health conditions. The COVID-19 pandemic, with its attendant anxiety and social isolation, likely will drive further demand for mental healthcare at a time when employers are eager to expand access.
Take inventory of virtual mental health offerings to ensure sufficient access to virtual care and support. Communicate these virtual options early and often to employees and members. Encourage the use of telehealth for mental health through plan design.
Build out virtual mental health services and integrate them with broader primary care services to improve health outcomes and spending on individuals with a comorbid mental health condition.
Partner with digital mental health companies to support medication adherence and enhance outcomes. Consider outcomes-based contracts with employers and payers for the diseases and related treatments targeted by partnerships with digital mental health companies.
Most medications in the pipeline are specialty drugs. Some of those drugs are curative gene therapies that could come with multimillion-dollar price tags. Existing specialty drugs also are driving spending as the conditions for which they are approved expands.
Self-insured employers and payers should evaluate their abilities to cover new, high-priced therapies and consider partnering with other organizations such as financial institutions, pharmaceutical companies and even other payers with the balance sheet to weather one-time treatment costs of $1 million or more.
Work with payers and employers to mitigate spending growth on administered drugs, most of which are high-priced specialty drugs, by delivering those therapies in the safest, lowest cost setting. During the COVID-19 pandemic, this could mean moving treatments completely out of the inpatient setting to an outpatient clinic, physician’s office or even the patient’s home.
Before the launch of a new drug, especially one with a price tag in the millions, engage with payers and employers on pricing and financing. Make the case for the long-term cost savings. Consider alternative payment models, or a combination of models, to ease the financial burden on payers and employers.
Telehealth has been gaining ground slowly for years. COVID-19 forced its rapid adoption by both consumers and clinicians, many of whom had never used it before. In 2021, HRI expects telehealth to settle in as a viable and desirable alternative to in-person care, saving employers and health plans on the episodic cost of care delivered virtually.
With telehealth utilization likely to remain up over pre-pandemic levels, payers should review their telehealth contracts and determine whether contracting with a national telehealth provider, local providers or both best fits the needs of its members. Payers can also help employers increase utilization of telehealth.
Providers should reevaluate telehealth solutions with the expectation that this channel for care delivery may be the new normal. Providers will need to redesign the patient experience for a post-pandemic world around a heavily virtual system that is able to address chronic conditions and more complicated patients.
Post-pandemic, companies should prepare for virtual clinical trials to become the norm. Virtual trials could lead to faster drug development, by allowing for faster collection of some data and more frequent gathering of information about patients.
Employers are eyeing narrow provider networks; over a quarter of employers have been considering them for the past few years. Some of those employers may move to a narrow network plan in 2021 as COVID-19 and the related economic downturn force employers to shed costs and make healthcare providers more willing in the short term to give price concessions or take on more risks in exchange for predictable cash flows, if it helps them get patients to return for care.
Plans that have embraced narrow networks for their individual exchange businesses may be well-positioned to roll out those networks on a broader scale for commercial large group business. Employers will need analytic capabilities to understand costs to inform strategy and a clear communication strategy to show value to employees, who may be skeptical of their value.
Providers positioning for inclusion in narrow networks will need to demonstrate quality while managing cost. They should pursue deals that help them build primary care networks that can address patients’ whole health needs, including addressing the social factors impacting their health, and triage patients to the lowest cost setting appropriate for their health issue.
As narrow provider networks become more popular, providers may be shouldering more risk on treatment and patient outcomes. This could affect prescribing patterns and, in turn, how pharmaceutical companies promote their products to providers. Pharmaceutical companies should find the most effective ways to demonstrate their drugs’ value and look for opportunities to collaborate with providers on population health management.
We are focused in a range of areas including: strategy, operations, technology, finance, people and change, risk and forensics.
We have a deep industry experience helping address major challenges in R&D, supply chain and sales and marketing. We work across a range of corporate functions, including regulatory compliance, IT, finance, human resources and business development, strategic transformation, clinical transformation, revenue cycle, operations and M&A strategy. Learn more.
We are a market leader in providing accounting and auditing services in the healthcare, pharmaceutical and life sciences industries. We work with the some of the largest global organizations in these industries as well as emerging and early stage companies, helping them prepare for and meet the requirements for accessing the public market as well as obtaining private equity or venture funding. Our aim is to deliver services that support your ability to provide corporate stakeholders with accurate and understandable financial and operational information about your business. Learn more.
We deliver highly focused, practical tax ideas and solutions. Our tax specialists provide the full spectrum of support from tax structuring and strategy through to compliance services (including co-sourcing and outsourcing).
We understand the industry and how tax concerns impact a wide range of areas such as R&D credits, transfer pricing, intellectual property management, treasury strategies, mergers, acquisitions and divestitures, Form 990 reporting, state and local planning and expansion of global programs. Learn more.
US Health Industries Leader, PwC US
Principal, Health and Welfare Practice Leader, PwC US
Principal, Health Industries, PwC US